Nursing Diagnosis for Anemia: 5 Sample Care Plans & Interventions

Choosing the right nursing diagnosis for anemia — and building a clean NANDA-I care plan around it — is something every nursing student has to do, often in their first med-surg semester and again every clinical rotation after that.

Anemia is one of the most common conditions you’ll see on the unit. It cuts across every age group, every floor, and most disease processes — chronic kidney disease, GI bleeds, cancer, pregnancy, sickle cell, post-op, the elderly patient who’s “just been more tired lately.”

This anemia nursing care plan walks through what to assess, the NANDA-I nursing diagnoses for anemia you’ll see most often, and 5 sample care plans you can model your clinical paperwork on for general anemia, iron deficiency, severe symptomatic anemia, sickle cell crisis, and aplastic / chemotherapy-related anemia.

It’s written for nursing students, new grads, and any RN who wants a refresher with current NANDA-I 2024–2026 language and AABB 2023 transfusion guidance baked in.

Scope note. This is an educational care plan for nursing students and new graduates. It is not a substitute for facility protocol, provider orders, or specialist clinical judgment. Always verify medication doses, transfusion thresholds, and escalation criteria against your institution’s current policy and the patient’s individualized plan of care.

Table of contents

• What is anemia?
• Types of anemia
• Signs and symptoms
• Nursing assessment
• Diagnostic studies and lab interpretation
• Iron, B12, and folate dosing
• Transfusion thresholds (AABB 2023)
• Nursing goals and outcomes
• Nursing interventions
• Nursing diagnosis for anemia — 5 sample care plans
• Sickle cell crisis at the bedside
• Neutropenic precautions
• Escalation red flags
• Discharge and patient teaching
• Practice question
• FAQs
• Related resources
• References

What is anemia?

Anemia is a reduction in red blood cells (RBCs) or hemoglobin (Hgb) that decreases the blood’s oxygen-carrying capacity. WHO categorizes anemia by hemoglobin level for nonpregnant adults as mild, moderate, or severe:

WHO hemoglobin cutoffs vary by age, sex, pregnancy status, altitude, smoking, and clinical setting — check the specific WHO table for your patient population. A hemoglobin value of < 6.5 g/dL is a clinical red flag that warrants urgent evaluation, but “life-threatening” is not a formal WHO severity category.

The severity of the symptoms, however, depends as much on how fast the anemia developed as the absolute number. A patient who’s been chronically anemic for months at Hgb 8 may walk around without dyspnea; a patient who acutely loses blood and drops from 13 to 9 may be in clinical distress.

Types of anemia

Anemia is most usefully classified by MCV (mean corpuscular volume) — the average RBC size:

You will also see these named anemia types repeatedly in clinical paperwork:

• Iron deficiency anemia — most common worldwide; chronic blood loss (heavy menses, GI bleed), dietary insufficiency, malabsorption (celiac, post-gastric-bypass)
• B12 (cobalamin) deficiency / pernicious anemia — autoimmune loss of intrinsic factor → B12 malabsorption; also vegan diet, ileal resection, metformin long-term, PPI long-term
• Folate deficiency — pregnancy, alcohol use, methotrexate, malnutrition
• Anemia of chronic disease (anemia of inflammation) — chronic kidney disease, autoimmune disease, malignancy
• Hemolytic anemia — autoimmune, drug-induced, mechanical (heart valve), microangiopathic (TTP, DIC), G6PD deficiency
• Aplastic anemia — pancytopenia from bone marrow failure (idiopathic, drug-induced, post-viral, chemotherapy)
• Sickle cell anemia — autosomal recessive hemoglobinopathy; chronic hemolysis with intermittent vaso-occlusive crises

Signs and symptoms

Cardinal signs (variable by severity and onset speed):

• Fatigue, weakness, decreased exercise tolerance
• Pallor (skin, conjunctiva, palmar creases, oral mucosa)
• Dyspnea on exertion, eventually at rest in severe cases
• Tachycardia, palpitations, systolic flow murmur
• Dizziness, lightheadedness, syncope
• Headache, difficulty concentrating, irritability
• Cold intolerance
• Brittle nails, koilonychia (“spoon nails” — classic iron deficiency)
• Glossitis, angular cheilitis (iron, B12, folate)
• Neurologic findings in B12 deficiency: paresthesias, ataxia, dementia (subacute combined degeneration — neuro symptoms may be irreversible if not treated early)
• Jaundice in hemolytic anemia
• Bone pain, vaso-occlusive pain, acute chest syndrome in sickle cell

Nursing assessment

A solid assessment is what makes the difference between a generic care plan and one with the right nursing diagnosis for anemia attached to it. Use a structured approach. The data below is what to consider, not what every patient with anemia will have.

Subjective data

• Onset and duration of fatigue / dyspnea / dizziness
• Bleeding history (menses, GI, gum, epistaxis, urinary)
• Dietary intake — iron-rich foods, vegetarian / vegan pattern, alcohol use
• Family history — thalassemia, sickle cell trait/disease, pernicious anemia, hereditary spherocytosis
• Medication review — chronic NSAID, PPI, metformin, methotrexate, anticoagulants, chemotherapy
• Pregnancy and obstetric history
• Surgical history — gastric bypass, gastrectomy, ileal resection
• Pain — sickle cell crisis location, character, severity

Objective data

• Vital signs (resting tachycardia, orthostatic changes)
• SpO₂ at rest and with ambulation
• Skin / conjunctiva / oral mucosa color
• Heart sounds (flow murmur, S₃ in high-output state)
• Lung sounds, respiratory effort
• Abdominal exam (splenomegaly in hemolytic anemia)
• Neuro exam if B12 suspected (vibration, proprioception, gait)
• Stool guaiac if GI bleed suspected
• Skin for petechiae / purpura / ecchymoses (aplastic, pancytopenia)
• Sickle cell crisis findings: localized bone/joint pain, swelling, fever, decreased oxygenation, mental status changes

Avoid absolute language. “Conjunctival pallor noted bilaterally” is more useful than “the patient is severely anemic on exam.” Document what you observe.

Diagnostic studies and lab interpretation

Quick pattern recognition for the most-tested findings:

• Iron deficiency: low Hgb, low MCV, high RDW, low ferritin, low iron, high TIBC, low TSAT. Ferritin can be normal or even elevated when iron deficiency coexists with inflammation — don’t rule out iron deficiency on ferritin alone in patients with chronic inflammatory disease.
• Anemia of chronic disease: low Hgb, normal or low MCV, normal or high ferritin (inflammation drives it up), low TIBC, low TSAT
• B12 / folate deficiency: low Hgb, high MCV, hypersegmented neutrophils, low B12 or folate
• Acute blood loss: Hgb may be normal initially (hemodilution lags ~24 h); then drops; reticulocytes climb within 3–5 days

Reticulocyte caveat. Reticulocyte response is best interpreted with an absolute or corrected reticulocyte count, not the raw percentage. In anemia, the percentage can mislead because the RBC denominator is reduced. A high reticulocyte response suggests blood loss or hemolysis; an inappropriately low response suggests underproduction — marrow suppression, CKD, iron deficiency, B12/folate deficiency, or inflammation. Lab reference ranges also vary by institution — check your facility’s normals.

Iron, B12, and folate dosing

Oral iron (iron deficiency anemia)

• Standard: ferrous sulfate 325 mg = ~65 mg elemental iron once daily
• Emerging evidence supports alternate-day dosing for better fractional absorption and fewer GI side effects
• Take with vitamin C if recommended or tolerated (orange juice or 250–500 mg ascorbic acid) — vitamin C may improve absorption for some patients
• Take on an empty stomach if tolerated; with food if GI upset
• Avoid taking iron with calcium, antacids, dairy, tea, or coffee (each can reduce absorption). For drug-drug spacing with levothyroxine, fluoroquinolones, tetracyclines, antacids, and calcium products, follow pharmacy and product-specific guidance — intervals differ by drug
• Common side effects: constipation, dark / black stools (normal, teach the patient), metallic taste, GI upset, nausea
• Treatment course: usually 3–6 months to restore ferritin once Hgb normalizes
• Switch to IV iron (iron sucrose, ferric carboxymaltose, ferric derisomaltose) for malabsorption, intolerance, CKD, or rapid replacement needs

Vitamin B12 (pernicious anemia)

• Cyanocobalamin 1,000 mcg IM daily x 1 week → weekly x 4 weeks → monthly for life (or per provider plan)
• High-dose oral 1,000–2,000 mcg/day shown comparable in some studies — useful when injection is impractical
• Patients with pernicious anemia need lifelong replacement
• Neurologic symptoms (paresthesias, ataxia) can become irreversible if treatment is delayed — escalate any new neuro change

Folate (folate deficiency)

• 1 mg PO daily for deficiency
• 400–800 mcg/day in pregnancy for neural tube defect prevention
• 4 mg/day in pregnancy for women with a prior neural-tube-defect pregnancy
• Do not treat suspected megaloblastic anemia with folate alone until B12 deficiency has been assessed — folate may improve the anemia while neurologic injury from untreated B12 deficiency continues

Erythropoiesis-stimulating agents (ESAs) — anemia of CKD or chemotherapy

ESAs (epoetin alfa, darbepoetin) may be used in anemia of CKD or chemotherapy-associated anemia when ordered, but therapy is individualized. In CKD, ESA initiation is commonly considered when Hgb is < 10 g/dL, based on symptoms, rate of decline, transfusion risk, iron status, and cardiovascular risk. Do not normalize hemoglobin; use the lowest effective dose, and avoid targets above 11 g/dL unless specialist guidance directs otherwise. Iron stores must be adequate before or during ESA therapy. Monitor for hypertension and thrombotic events.

Transfusion thresholds (AABB 2023)

The current AABB clinical practice guideline supports a restrictive transfusion strategy for most patients:

Restrictive ≠ never transfuse. A patient with active hemodynamic compromise (severe tachycardia, hypotension, ongoing bleeding, ischemia, or symptomatic anemia) may be transfused at higher thresholds — clinical judgment plus provider order always overrides a number.

Nursing transfusion essentials:

• Two-RN identifier check at bedside before initiation
• Baseline vitals → vitals at 15 minutes → vitals after each unit
• Start slowly (usually 75 mL/h or less for the first 15 minutes), then increase as tolerated; complete each unit within 4 hours
• Stop the transfusion immediately and notify provider for any reaction signs: fever, chills, urticaria, dyspnea, back pain, hypotension, tachycardia, change in mental status
• Document pre-transfusion, mid-transfusion, and post-transfusion vitals and any reaction

Nursing goals and outcomes

Once you’ve picked the nursing diagnosis for anemia that fits the patient’s actual presentation, your goals flow directly from it. By the end of the shift / hospitalization, the patient will (choose what fits the individual patient):

• Maintain SpO₂ within their individualized target range (typically ≥ 92% on room air).
• Tolerate progressive ambulation without dyspnea or SpO₂ drop > 4% from baseline.
• Verbalize three early signs of worsening anemia and when to call the provider.
• Demonstrate accurate oral iron self-administration (timing, vitamin C, GI side-effect management).
• State the importance of follow-up CBC at the interval ordered (typically 2–4 weeks after iron initiation, then 3 months).
• Identify three dietary sources of iron, B12, or folate appropriate to their diagnosis.
• Maintain hemodynamic stability — HR within 20% of baseline, BP within 20 mm Hg of baseline.

Use SMART framing and add function-based goals where possible — “walks the hallway twice without needing to stop” is more useful than “tolerates activity.”

Nursing interventions

Activity and oxygenation

• Plan rest periods between activities; cluster care to maximize uninterrupted rest.
• Monitor SpO₂ at rest and with ambulation; treat hypoxia with supplemental oxygen per provider order.
• Position upright for dyspnea; teach pursed-lip breathing if helpful.
• Progressive activity per tolerance — stop and reassess for SpO₂ drop, tachycardia, chest discomfort, dizziness.

Lab and hemodynamic monitoring

• Trend serial CBC, reticulocyte count, iron studies, B12 / folate.
• Track vital sign trends, especially HR and orthostatic BP.
• Recognize transfusion thresholds (see above) and watch for transfusion reactions when administering RBCs.

Medication administration

• Administer oral iron, B12, folate, ESAs, hydroxyurea, or transfusion products per provider order.
• Teach side-effect expectations (iron: dark stools, constipation; ESAs: hypertension).
• Coordinate with pharmacy on drug-drug interactions (calcium, levothyroxine, fluoroquinolones, tetracyclines all interact with oral iron — separate by ≥ 2 hours).

Nutrition

• Coordinate dietitian consult for iron-rich, B12-rich, or folate-rich meal planning as appropriate.
• Iron sources: red meat, poultry, fish, fortified cereals, beans, lentils, dark leafy greens.
• B12 sources: animal products primarily; fortified plant milks / cereals for vegetarians/vegans.
• Folate sources: leafy greens, citrus, fortified grains, beans.

Skin and bleeding precautions

• For thrombocytopenia (aplastic, chemotherapy, hypersplenism): soft toothbrush, electric razor, no IM injections when possible, fall precautions, no NSAIDs / aspirin / anticoagulants unless ordered.
• For severely anemic patients: skin assessment (poor perfusion increases pressure-injury risk).

Infection prevention

• Neutropenic precautions when ANC < 1,000 (see neutropenic precautions section).

Education

• Reinforce diet, medication, activity, and follow-up plan with teach-back at every encounter.
• Link to nursing diagnosis and nursing interventions refreshers for student-facing context.

Nursing diagnosis for anemia — 5 sample care plans

These five care plans cover the nursing diagnoses for anemia you’ll see most often in clinical paperwork. Each uses NANDA-I-style nursing diagnosis language, current clinical guidance (AABB 2023, ASH, NIH), and the standard student template (diagnosis → defining characteristics / risk factors → goals → interventions with rationales → evaluation). Verify exact NANDA-I 2024–2026 labels, definitions, defining characteristics, and related / risk factors against your licensed NANDA-I text before using them for graded clinical paperwork.

NANDA-I label verification. NANDA-I diagnoses, definitions, defining characteristics, and related / risk factors are updated by edition (the 2024–2026 edition added 56 new diagnoses and revised 123). Before using any of these care plans for graded clinical paperwork or institutional documentation, verify the exact label, definition, and defining characteristics against your licensed NANDA-I 2024–2026 text. Where a related but distinct current label may apply, we’ve noted it.

Care Plan #1 — Activity Intolerance

This is the most-used nursing diagnosis for anemia. It applies to almost any patient with moderate-to-severe symptomatic anemia who’s struggling with ADLs.

Scenario. A 68-year-old woman with chronic kidney disease, Hgb 8.4 g/dL, MCV 88. Reports she “can’t even walk to the mailbox anymore without resting.” HR 102 at rest, climbs to 124 with ambulation across the room. SpO₂ 95% at rest, drops to 91% with activity.

Diagnosis (NANDA-I 2024–2026)

Activity Intolerance related to imbalance between oxygen supply and demand secondary to decreased hemoglobin and red blood cell mass, as evidenced by patient-reported dyspnea on minimal exertion, resting tachycardia, SpO₂ drop with activity, and inability to complete ADLs without rest.

Goals

• By end of shift, the patient ambulates 25 feet without SpO₂ dropping below 92% and HR climbing > 20% above baseline.
• Before discharge, the patient identifies three energy-conservation strategies and verbalizes a return-to-activity plan.
• The patient maintains an upward Hgb trend on serial CBC during the admission.

Interventions and rationales

Evaluation

• Did the patient meet the activity goal without SpO₂ or HR breach?
• Did the patient teach back energy-conservation techniques?
• Is the Hgb trending upward on serial CBC?

Care Plan #2 — Imbalanced Nutrition: Less than Body Requirements

Common diagnosis for iron-deficiency anemia, B12 deficiency, or folate deficiency tied to dietary pattern, GI absorption, or chronic blood loss.

Scenario. A 29-year-old vegetarian woman, heavy menstrual periods, Hgb 9.6, MCV 72, ferritin 8 ng/mL, TSAT 9%. Reports she doesn’t eat red meat and “didn’t know vegetarians could get anemic.”

Diagnosis (NANDA-I 2024–2026)

Imbalanced Nutrition: Less than Body Requirements related to inadequate dietary iron intake and increased iron loss from menorrhagia, as evidenced by Hgb 9.6 g/dL, MCV 72 fL, ferritin 8 ng/mL, and patient-reported absence of dietary iron sources.

Goals

• The patient identifies three iron-rich foods compatible with her diet by end of teaching session.
• The patient demonstrates correct oral iron self-administration with vitamin C by end of teaching session.
• Ferritin rises and Hgb climbs ≥ 1 g/dL within 4 weeks of iron initiation.

Interventions and rationales

Evaluation

• Has the patient identified iron-rich foods and started taking iron correctly?
• Are Hgb and ferritin trending up at follow-up labs?
• Has the menorrhagia work-up been initiated?

Care Plan #3 — Decreased Cardiac Output

Severe symptomatic anemia, often pre-transfusion. Body compensates with tachycardia and increased stroke volume; eventually CO falls and tissue perfusion suffers.

Scenario. A 74-year-old man with coronary artery disease, GI bleed (melena), Hgb 6.5 g/dL on admission. HR 118, BP 96/58, orthostatic drop of 22 mm Hg systolic. Reports new chest discomfort with ambulation. Pre-transfusion candidate per AABB (Hgb < 8 with cardiovascular disease).

Diagnosis (NANDA-I 2024–2026)

Decreased Cardiac Output related to reduced oxygen-carrying capacity and altered preload from severe anemia, as evidenced by Hgb 6.5 g/dL, resting tachycardia, orthostatic hypotension, exertional chest discomfort, and new dyspnea at rest.

Goals

• The patient maintains HR < 110, SBP > 100, and resolution of chest discomfort during hospitalization.
• The patient receives transfusion per AABB threshold (Hgb < 8 with CV disease) without reaction.
• The patient identifies the bleeding source with the medical team and initiates GI work-up before discharge.

Interventions and rationales

Evaluation

• Did vital signs stabilize?
• Was the transfusion completed without reaction?
• Has the GI source been identified / treatment plan in place?

Care Plan #4 — Acute Pain (sickle cell vaso-occlusive crisis)

Sickle cell disease patients often present in vaso-occlusive crisis — severe pain from sickled RBCs occluding the microvasculature.

Scenario. A 24-year-old patient with known sickle cell disease (HbSS), baseline Hgb ~8.0, presents to ED with severe bilateral hip and back pain rated 9/10. Hgb 7.2. Reports the same pain pattern as her prior crises. T 38.0 °C, HR 112, SpO₂ 94%.

Diagnosis (NANDA-I 2024–2026)

Acute Pain related to vaso-occlusion of microvasculature by sickled red blood cells, tissue hypoxia, and inflammatory response, as evidenced by patient-reported pain 9/10 in the bilateral hips and back, restless positioning, tachycardia, and history consistent with prior crises.

Goals

• Within 60 minutes of arrival, the patient receives IV opioid analgesia and reports pain decrease ≥ 2 points on a 0–10 scale.
• Within 4 hours, the patient is comfortable enough to rest and is taking PO fluids.
• The patient is screened for crisis triggers (dehydration, infection, hypoxia, cold exposure) and a plan to avoid them at discharge.

Interventions and rationales

Evaluation

• Did pain decrease meaningfully on serial reassessment?
• Was a trigger identified and addressed?
• No signs of acute chest syndrome?

Care Plan #5 — Risk for Bleeding (aplastic / chemotherapy-related pancytopenia)

Aplastic anemia or chemotherapy-induced pancytopenia means low RBCs, low platelets, low WBCs simultaneously — bleeding precautions and infection prevention overlap.

Scenario. A 41-year-old patient with acute myeloid leukemia, day 14 post-induction chemotherapy. Hgb 7.8, platelets 18,000, ANC 280. Reports mild gum bleeding when brushing teeth this morning. Petechiae noted on lower legs.

Diagnosis (NANDA-I 2024–2026)

Risk for Bleeding related to chemotherapy-induced thrombocytopenia, bone marrow suppression, and underlying hematologic malignancy.

(Risk-for diagnoses use “related to” only — no “as evidenced by.”)

Goals

• The patient remains free of major bleeding (no GI, GU, intracranial, or significant mucosal bleeding) during the admission.
• Platelets remain stable or improve with transfusion support per facility threshold (often platelet transfusion if < 10K, or < 20K with bleeding / fever).
• The patient verbalizes bleeding precautions and identifies three signs that require immediate provider notification.

Interventions and rationales

Evaluation

• Did the patient remain free of major bleeding?
• Were neutropenic and bleeding precautions maintained?
• Did the patient teach back signs to report?

Sickle cell crisis at the bedside

A quick reference for nursing students who may not see sickle cell crisis often:

• First 60 minutes are the priority window — get analgesia in, get fluids running, screen for triggers.
• No meperidine. Use morphine or hydromorphone IV per provider order.
• Give supplemental oxygen for hypoxemia, respiratory symptoms, or suspected acute chest syndrome. Routine oxygen is not necessary for every vaso-occlusive crisis if oxygenation is normal. In acute chest syndrome, oxygen is used to maintain SpO₂ ≥ 95% along with urgent evaluation, antibiotics when indicated, fluid management, and possible transfusion or exchange transfusion (NHLBI guidance).
• Hydration, not over-hydration. Isotonic IVF at maintenance is typical; aggressive boluses risk pulmonary edema and acute chest syndrome.
• Acute chest syndrome — new pulmonary infiltrate plus respiratory symptoms or fever — is the leading cause of mortality and requires urgent intervention (oxygen, fluid management, antibiotics, possible exchange transfusion).
• Patients with sickle cell disease who repeatedly come to the ED often face bias and stigma around opioid use. Treat the pain. Their reports of pain pattern should be trusted.

Neutropenic precautions

Initiate when ANC < 1,000 cells/μL; intensify when < 500.

Standard interventions:

• Strict hand hygiene before any contact
• Use a private room when available and follow facility neutropenia policy. Protective-environment rooms with HEPA filtration are generally reserved for select highest-risk patients (such as allogeneic hematopoietic stem cell transplant recipients) — not every patient with severe neutropenia.
• No fresh flowers or live plants
• Meticulous food safety, not a blanket raw-produce ban: avoid raw or undercooked meat, poultry, seafood, and eggs; avoid unpasteurized dairy or juices; avoid raw sprouts; wash fruits and vegetables carefully; follow facility or oncology / transplant-specific restrictions. ASCO does not recommend a neutropenic diet that excludes all raw fruits and vegetables as routine cancer-treatment infection prevention.
• Daily skin, oral, and IV-site inspection
• No rectal procedures (no rectal temperatures, suppositories, or enemas)
• Visitors screened — no one with active infection
• Fever in a neutropenic patient (single oral temp ≥ 38.3 °C or sustained ≥ 38.0 °C for an hour) is a medical emergency — blood cultures and empiric broad-spectrum antibiotics typically within an hour

Escalation red flags

Discharge and patient teaching

Practice question

The nurse is caring for a 70-year-old patient with chronic kidney disease and a Hgb of 8.2 g/dL. Which of the following nursing actions are appropriate? (Select all that apply.)

• A. Encourage the patient to ambulate as much as possible to maintain conditioning
• B. Monitor SpO₂ at rest and with ambulation
• C. Coordinate erythropoiesis-stimulating agent administration per provider order if Hgb < 10
• D. Plan rest periods between activities
• E. Withhold the patient’s scheduled antihypertensive because of low Hgb

Answer: B, C, D.

• B — SpO₂ monitoring is appropriate for any symptomatic anemic patient.
• C — ESA use may be appropriate in CKD anemia when ordered and individualized. Iron stores should be assessed first; do not normalize hemoglobin; use the lowest effective dose; specialist input on targets and timing is the standard.
• D — Activity pacing reduces oxygen demand.
• A — Push-to-ambulate is not appropriate; energy conservation matters more here.
• E — Antihypertensives are not held for anemia alone; verify with provider but don’t act independently.

FAQs

What is the most common nursing diagnosis for anemia?

There is no single “most common” nursing diagnosis for anemia — it depends on the patient. The most-used NANDA-I 2024–2026-style labels for people with anemia include Activity Intolerance, Imbalanced Nutrition: Less than Body Requirements, Decreased Cardiac Output (severe symptomatic), Acute Pain (sickle cell crisis), and Risk for Bleeding (aplastic or pancytopenic patients). Pick the one that fits the patient’s actual presentation, and verify the exact label against your licensed NANDA-I 2024–2026 text.

What’s the difference between iron deficiency anemia and anemia of chronic disease?

Iron deficiency shows low Hgb with microcytic indices (MCV < 80), low ferritin, low iron, high TIBC. Anemia of chronic disease shows low Hgb with normal or low MCV, but high or normal ferritin (because inflammation drives ferritin up), low iron, low TIBC. Ferritin is the most useful discriminator.

How quickly should you correct severe anemia?

That depends on the cause and patient stability. For active bleeding or severe symptomatic anemia, transfusion is fast. For chronic iron deficiency anemia, oral iron usually replaces ferritin over 3–6 months. Don’t expect Hgb to normalize for 4–8 weeks even with appropriate therapy.

Why shouldn’t meperidine (Demerol) be used in sickle cell crisis?

Meperidine’s metabolite, normeperidine, accumulates with repeated dosing and can cause seizures, particularly in patients with renal impairment. Sickle cell crisis is usually treated with morphine or hydromorphone instead, per current pain-management guidance.

When should a patient with anemia be transfused?

AABB 2023 supports a restrictive threshold — Hgb < 7 g/dL for most hospitalized stable adults, Hgb < 8 g/dL for those with preexisting cardiovascular disease or undergoing orthopedic surgery. Clinical judgment (active bleeding, hemodynamic instability, symptomatic ischemia) can override the number.

Why is folate alone dangerous if B12 status is unknown?

Folate can correct the megaloblastic anemia of combined B12 / folate deficiency, but it doesn’t fix the underlying B12 deficiency. The neurologic damage from B12 deficiency (subacute combined degeneration) can continue and become irreversible. Always check B12 status before treating with folate alone.

Related resources

• Nursing Diagnosis — full NANDA-I guide
• Nursing Interventions — independent, dependent, collaborative interventions explained
• Nursing Care Plan Template — fillable template you can adapt for any patient
• Nursing Process — the 5-step framework refresher
• ADPIE — Assessment, Diagnosis, Planning, Implementation, Evaluation
• Decreased Cardiac Output Nursing Diagnosis — companion care plan often paired with severe anemia

References

1. Herdman TH, Kamitsuru S, Lopes CT (eds). NANDA International Nursing Diagnoses: Definitions and Classification, 13th ed., 2024–2026. Thieme. https://nanda.org/
2. World Health Organization. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations (2024). https://www.who.int/publications/i/item/9789240088542
3. Carson JL, Stanworth SJ, Dennis JA, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA. 2023. https://jamanetwork.com/journals/jama/fullarticle/2810195
4. Estcourt LJ, Birchall J, Allard S, et al. AABB / ICTMG Platelet Transfusion Guidelines (2025 update). http://www.aabb.org/standards-accreditation/standards/platelet-transfusion-guidelines
5. KDIGO. Clinical Practice Guideline for Anemia in Chronic Kidney Disease. https://kdigo.org/guidelines/anemia-in-ckd/
6. American Society of Hematology. ASH 2020 Guidelines for Sickle Cell Disease: Management of Acute and Chronic Pain. https://ashpublications.org/bloodadvances/article/4/12/2656/461036
7. U.S. Food and Drug Administration. FDA Drug Safety Communication — Pfizer Voluntarily Withdraws Oxbryta (voxelotor) from All Markets (September 2024). https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-patients-and-health-care-professionals-voluntary-withdrawal-oxbryta-voxelotor-market
8. National Institutes of Health, Office of Dietary Supplements. Vitamin B12 — Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
9. National Institutes of Health, Office of Dietary Supplements. Iron — Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/
10. Centers for Disease Control and Prevention. Iron and Iron Deficiency. https://www.cdc.gov/nutrition/about-nutrition/micronutrient-malnutrition/iron-and-iron-deficiency.html
11. National Library of Medicine (NCBI Bookshelf). Anemia. https://www.ncbi.nlm.nih.gov/books/NBK499994/
12. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. American Journal of Hematology. https://onlinelibrary.wiley.com/doi/10.1002/ajh.24820
13. Stabler SP. Vitamin B12 Deficiency. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMcp1113996

Source notes. NANDA-I diagnoses, definitions, defining characteristics, and related / risk factors should be verified in the licensed NANDA-I 2024–2026 text before clinical documentation. ASH Clinical Practice Guidelines and the AABB Red Blood Cell Transfusion guidance are updated periodically — always cite the most current edition. Always consult facility protocol for transfusion thresholds, neutropenic precautions, and sickle cell crisis management.